A Study of C-MYC, SOX10 and BCL-2 Proteins Expression in Head and Neck Mucosal Melanomas
DOI:
https://doi.org/10.6000/1929-2279.2016.05.04.1Keywords:
Mucosal melanoma, C-MYC, SOX10, BCL-2.Abstract
Background: Head and Neck Mucosal Melanoma (HNMM) is rare, accounting 1% of all melanomas in USA, and 6% in Japan. Melanoma’s development is a complex process involving activation of proto-oncogenes and loss of tumor suppressors. BCL-2 oncogene encodes a family of anti-apoptotic proteins and it is overexpressed in melanomas. On the other hand, proto-oncogene C-MYC is a transcriptional factor and plays crucial role both in driving cell proliferation and promoting apoptosis, its overexpression has been associated to melanoma progression. Moreover, oncogene SOX10 cooperates with other transcription factors to direct the development and differentiation of melanocytes. These three nuclear markers are associated to melanoma’s metastatic risk.Methods: We studied of BCL-2; C-MYC and SOX10 proteins in 19 Formalin Fixed Paraffin Embedded cases of HNMM from Yale School of Medicine and 10 cases from University of São Paulo by Alkalin Phosphatase immunohistochemistry technique.Results: We considered as positive expression when over 25% of tumor cells were immunostained. We observed 27/29 were positive to BCL-2 and 28/29 cases showed SOX10 expression (both markers showing immunostaining in over 75% of tumor cells). However, we noticed variable expression for C-MYC in 15/29 of HNMM cases.Conclusions: According to ours results, we suggest that BCL-2 and SOX10, should be good adjuctive biomarkers for HNMM, however lower expression of C-MYC has not shown to play main role in the HNMM development, thus further molecular biology studies should corroborate this present study.
Downloads
Published
Issue
Section
How to Cite
Similar Articles
- Alberto Modenese, Preventing Melanoma with the Help of Occupational Physicians , Journal of Cancer Research Updates: Vol. 5 No. 4 (2016)
- Kevan B. Tucker, Kristina L. Makey, Edmund Chinchar, Min Huang, Natale Sheehan, Srinivasan Vijayakumar, Jian-Wei Gu, EGCG Suppresses Melanoma Tumor Angiogenesis and Growth without Affecting Angiogenesis and VEGF Expression in the Heart and Skeletal Muscles in Mice , Journal of Cancer Research Updates: Vol. 3 No. 1 (2014)
- Ricardo Hsieh, The Role of BRAF Gene in Cancer: Literature Review and Future Directions , Journal of Cancer Research Updates: Vol. 9 No. 1 (2020)
- Giovanni Luigi Capella, Do "Incidental Melanomas" Exist? If so, how many are they? High Time to Decide , Journal of Cancer Research Updates: Vol. 8 No. 1 (2019)
- Omar A. Dupuy L. , José A. Bonilla V., Renato Murillo M., Peter Taylor, María J. Abad, Lorena I. González P., Olmedo Otero, Johanna Juliao A., In Vitro Evaluation of the Antiinflammatory and Anticancer Activities of Compounds from the Plants Casearia sylvestris and Zanthoxylum monophyllum , Journal of Cancer Research Updates: Vol. 4 No. 3 (2015)
- Jiaqiong Wang, Robert Carroll, Editorial: PET/CT for Cancer Diagnosis, Staging and Prognosis , Journal of Cancer Research Updates: Vol. 5 No. 1 (2016)
- Ciro Comparetto, Franco Borruto, Molecular Technologies in Gynecologic Oncology , Journal of Cancer Research Updates: Vol. 4 No. 4 (2015)
- Alfred Böcking, David Friedrich, Branko Palcic, Dietrich Meyer-Ebrech, Jin Chen, Diagnostic and Prognostic DNA-Karyometry for Cancer Diagnostics , Journal of Cancer Research Updates: Vol. 9 No. 1 (2020)
- Tatiana I. Bulycheva, Svetlana A. Mayakova, Simon V. Skurkovich , Disease-Free Remission Exceeding 37 Years in Patients Treated as Children for Acute Leukemia (AL) with Immunotherapy Using Viable (Cryopreserved) Allogeneic Leukemic Cells Pages 254-26 , Journal of Cancer Research Updates: Vol. 2 No. 4 (2013)
- Naveen Karuvandan, Pradeep Ventrapati, Real-World Clinical Outcomes of Ujvira® (Trastuzumab Emtansine Biosimilar) in HER2-Positive Breast Cancer: A Retrospective Observational Study in Indian Patients , Journal of Cancer Research Updates: Vol. 14 (2025)
You may also start an advanced similarity search for this article.